2018
DOI: 10.1016/j.cell.2018.07.034
|View full text |Cite
|
Sign up to set email alerts
|

Comprehensive Characterization of Cancer Driver Genes and Mutations

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

14
485
1

Year Published

2019
2019
2021
2021

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 470 publications
(500 citation statements)
references
References 0 publications
14
485
1
Order By: Relevance
“…CTNNB1 mutation frequencies were assessed in 10 100 common cancers from The Cancer Genome Atlas (TCGA) (Bailey et al ., ; Gao et al ., ), including 175 pancreatic ADCs. In addition, mutational data from 8 SPNs from Wu et al .…”
Section: Methodsmentioning
confidence: 99%
“…CTNNB1 mutation frequencies were assessed in 10 100 common cancers from The Cancer Genome Atlas (TCGA) (Bailey et al ., ; Gao et al ., ), including 175 pancreatic ADCs. In addition, mutational data from 8 SPNs from Wu et al .…”
Section: Methodsmentioning
confidence: 99%
“…Data from The Cancer Genome Atlas (TCGA) as part of the Pan‐Cancer Initiative have confirmed the role of TP53 as the most prominent cancer driver gene . The most recent study covering over 9000 tumour exomes across over 30 different cancer types found TP53 mutations to be associated with 27 cancer types . Mutant p53 proteins can accumulate in cancer cells harbouring the mutant genes.…”
Section: Introductionmentioning
confidence: 99%
“…Yet, within the SOX family, SOX17 has the highest mutation rate followed by SOX9 and SOX2. Accordingly, SOX17 and SOX9 have been classified as mutational cancer drivers by The Cancer Genome Atlas in endometrial cancer and colorectal adenocarcinoma, respectively . Therefore, dissecting the functional impact of missense mutations is of particular interest to these SOX factors.…”
Section: Resultsmentioning
confidence: 99%
“…SOX17 has been classified as ‘likely oncogene’ in endometrial cancer for the presence of recurring missense mutations . Yet, dedicated analysis predicts that WT SOX17 acts as a tumor suppressor by antagonizing the canonical Wnt/β‐catenin pathway .…”
Section: Discussion and Outlookmentioning
confidence: 99%
See 1 more Smart Citation